Turning Point Brands' white pouch nicotine sales rose 34% to $24.2M in Q1, but operating income fell on higher SG&A. The stock trades at 14x EBITDA guidance.
Alpha Score of 40 reflects weak overall profile with poor momentum, strong value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Turning Point Brands (NYSE:TPB) reported first-quarter results last month that showed revenue growth driven by its white pouch nicotine products, ALP and FRE. Total revenue rose to $97.2 million from $93.3 million a year earlier. Gross profit increased to $53.6 million from $50.2 million. Net income came in at $4.1 million, down from $5.3 million in the prior-year period.
The company's Modern Oral segment, which includes the ALP and FRE brands, posted revenue of $24.2 million, up from $18.1 million. That segment now accounts for roughly 25% of total revenue, up from 19% a year ago. The growth came as Turning Point expanded distribution of the white pouch products into additional convenience store chains and online channels.
Smoking Products, the legacy business built around Zig-Zag rolling papers and wraps, generated $57.3 million in revenue, flat versus $57.2 million a year earlier. The segment remains the largest contributor to top-line revenue but is not growing. Creative Distribution, which includes cigar wraps and other accessories, brought in $15.7 million, down from $18 million.
The margin picture was mixed. Gross margin narrowed to 55.1% from 53.8%, reflecting higher input costs and promotional spending on the newer nicotine pouch products. Selling, general and administrative expenses rose to $41.8 million from $38.7 million, partly tied to marketing for ALP and FRE. Operating income fell to $11.8 million from $13.6 million.
Turning Point ended the quarter with $52.1 million in cash and $200 million in total debt. The company generated $7.3 million in cash from operations, down from $12.1 million in the year-ago period. Free cash flow was $4.1 million.
Management reiterated full-year revenue guidance of $400 million to $415 million, with adjusted EBITDA in the range of $73 million to $78 million. The midpoint of that range implies roughly flat EBITDA growth from the $75.5 million reported in 2024.
The stock trades at about 14 times the midpoint of adjusted EBITDA guidance. That is below the broader consumer staples group but above where the stock has historically traded relative to its own revenue growth rate. The valuation reflects the market pricing in the Modern Oral growth story while discounting the flat legacy business and the rising spend needed to sustain pouch distribution gains.
Turning Point's Alpha Score sits at 40 out of 100, a Mixed label from AlphaScala's proprietary model. The score reflects the tension between the revenue acceleration in Modern Oral and the margin compression and cash flow decline in the reported quarter. The next quarterly report, due in early August, will show whether the white pouch growth rate is accelerating or plateauing, and whether the margin trend stabilizes or deteriorates further.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.